Aribio and Aribio Lab are entering the Indonesian market with four self-developed hyaluronic acid (HA) fillers.
On September 8, Aribio Group announced that its next-generation HA filler brand, 'Bidan,' has received final product approval from Indonesia's Food and Drug Administration (BPOM). Indonesia, with a population of approximately 300 million, is the world's fourth most populous country and has seen growth in its skincare market alongside economic development.
With this approval, Aribio Group is entering discussions with global aesthetic companies for the supply and launch of the fillers. The company plans to secure distribution channels and rapidly increase market share in collaboration with local major partners.
'Bidan' is an HA filler developed over seven years in partnership with university hospitals, targeting the anti-aging and medical aesthetic markets. According to the company, it utilizes its proprietary Precise Control Refinement Technique (PCRT) to enhance the homogeneity and viscoelasticity of HA particles. The product aims to achieve a soft particle composition and properties suitable for its intended use, as suggested by its name, 'Bidan.'
The company also applied the HCCL method, which reduces residual cross-linking agents. This technology minimizes potential immune reactions and side effects after filler procedures and reduces heavy metal residues. 'Bidan' received domestic marketing approval after confirming biocompatibility, efficacy, and safety through human application tests conducted by Professor Heo Chang-hoon’s team at Seoul National University Hospital.
Meanwhile, this year, the total value of technology export contracts for domestic pharmaceutical and biotech companies has surpassed 21 trillion won. Aribio's contract, valued at over 7 trillion won, follows similar large-scale agreements by Hanmi Pharmaceutical and Alteogen.
Aribio Group is simultaneously developing treatments for Alzheimer's disease and aesthetic products. The company is currently analyzing data ahead of the global Phase 3 clinical trial results for its oral Alzheimer's treatment, 'AR1001,' and plans to expand the export of anti-aging products, including fillers.
On September 8, Aribio Group announced that its next-generation HA filler brand, 'Bidan,' has received final product approval from Indonesia's Food and Drug Administration (BPOM). Indonesia, with a population of approximately 300 million, is the world's fourth most populous country and has seen growth in its skincare market alongside economic development.
With this approval, Aribio Group is entering discussions with global aesthetic companies for the supply and launch of the fillers. The company plans to secure distribution channels and rapidly increase market share in collaboration with local major partners.
'Bidan' is an HA filler developed over seven years in partnership with university hospitals, targeting the anti-aging and medical aesthetic markets. According to the company, it utilizes its proprietary Precise Control Refinement Technique (PCRT) to enhance the homogeneity and viscoelasticity of HA particles. The product aims to achieve a soft particle composition and properties suitable for its intended use, as suggested by its name, 'Bidan.'
The company also applied the HCCL method, which reduces residual cross-linking agents. This technology minimizes potential immune reactions and side effects after filler procedures and reduces heavy metal residues. 'Bidan' received domestic marketing approval after confirming biocompatibility, efficacy, and safety through human application tests conducted by Professor Heo Chang-hoon’s team at Seoul National University Hospital.
Meanwhile, this year, the total value of technology export contracts for domestic pharmaceutical and biotech companies has surpassed 21 trillion won. Aribio's contract, valued at over 7 trillion won, follows similar large-scale agreements by Hanmi Pharmaceutical and Alteogen.
Aribio Group is simultaneously developing treatments for Alzheimer's disease and aesthetic products. The company is currently analyzing data ahead of the global Phase 3 clinical trial results for its oral Alzheimer's treatment, 'AR1001,' and plans to expand the export of anti-aging products, including fillers.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.